Experiments were carried out on carburizing and temperature rising of the semi steel melt in a plasma induction furnace.Influence of many factors, such as power supply mode,position of the plasma torch and bottom b...Experiments were carried out on carburizing and temperature rising of the semi steel melt in a plasma induction furnace.Influence of many factors, such as power supply mode,position of the plasma torch and bottom blown gas stirring,on heating efficiency and melt temperature distribution was studied. Melt temperature could be effectively controlled by plasma heating,and carbon content of semi steel melt increased from 1.92 % to 4.58 %, and the utilization rate of carbon reached up to 61.57 % during carburizing of the melt.展开更多
用纯化的塞尼卡病毒(Seneca Valley virus,SVV)VP1蛋白,辅以不同佐剂免疫小鼠,分别从体液免疫及细胞免疫对小鼠的免疫效果进行评估。结果表明,VP1-AL组与VP1-FCA组的特异性抗体一免后7 d均呈显著上升趋势,PBS组变化不明显。二免后14 d,V...用纯化的塞尼卡病毒(Seneca Valley virus,SVV)VP1蛋白,辅以不同佐剂免疫小鼠,分别从体液免疫及细胞免疫对小鼠的免疫效果进行评估。结果表明,VP1-AL组与VP1-FCA组的特异性抗体一免后7 d均呈显著上升趋势,PBS组变化不明显。二免后14 d,VP1-FCA组特异性抗体效价达到最高值(1∶163840),PBS组抗体效价是1∶16(P<0.01);VP1-AL组特异性抗体效价达到最高值(1∶5120),PBS组抗体效价是1∶16(P<0.01)。中和抗体效价,二免后7 d VP1-FCA组达到最高值(1∶512),PBS组抗体效价是1∶8(P<0.01);二免后14 d VP1-AL组达到最高值(1∶1024),PBS组抗体效价是1∶16(P<0.01)。小鼠T淋巴细胞亚群CD3^(+)CD4^(+)与CD3^(+)CD8^(+)在二免后VP1-FCA组显著升高(P<0.05),VP1-AL组极显著升高(P<0.01)。淋巴细胞增殖试验表明各试验组均显著升高(P<0.05)。对免疫小鼠血清中细胞因子检测结果表明,IL-4的分泌显著提高(P<0.05),IL-2与IFN-γ变化不明显。本研究利用SVV VP1重组蛋白联合佐剂,VP1-AL组是有前景的候选疫苗,可诱导小鼠体内产生免疫应答且效果良好,为SVV疫苗猪体免疫研究奠定理论基础。展开更多
文摘Experiments were carried out on carburizing and temperature rising of the semi steel melt in a plasma induction furnace.Influence of many factors, such as power supply mode,position of the plasma torch and bottom blown gas stirring,on heating efficiency and melt temperature distribution was studied. Melt temperature could be effectively controlled by plasma heating,and carbon content of semi steel melt increased from 1.92 % to 4.58 %, and the utilization rate of carbon reached up to 61.57 % during carburizing of the melt.
文摘用纯化的塞尼卡病毒(Seneca Valley virus,SVV)VP1蛋白,辅以不同佐剂免疫小鼠,分别从体液免疫及细胞免疫对小鼠的免疫效果进行评估。结果表明,VP1-AL组与VP1-FCA组的特异性抗体一免后7 d均呈显著上升趋势,PBS组变化不明显。二免后14 d,VP1-FCA组特异性抗体效价达到最高值(1∶163840),PBS组抗体效价是1∶16(P<0.01);VP1-AL组特异性抗体效价达到最高值(1∶5120),PBS组抗体效价是1∶16(P<0.01)。中和抗体效价,二免后7 d VP1-FCA组达到最高值(1∶512),PBS组抗体效价是1∶8(P<0.01);二免后14 d VP1-AL组达到最高值(1∶1024),PBS组抗体效价是1∶16(P<0.01)。小鼠T淋巴细胞亚群CD3^(+)CD4^(+)与CD3^(+)CD8^(+)在二免后VP1-FCA组显著升高(P<0.05),VP1-AL组极显著升高(P<0.01)。淋巴细胞增殖试验表明各试验组均显著升高(P<0.05)。对免疫小鼠血清中细胞因子检测结果表明,IL-4的分泌显著提高(P<0.05),IL-2与IFN-γ变化不明显。本研究利用SVV VP1重组蛋白联合佐剂,VP1-AL组是有前景的候选疫苗,可诱导小鼠体内产生免疫应答且效果良好,为SVV疫苗猪体免疫研究奠定理论基础。